The Taiwanese Association of Diabetes Educators, the Taiwanese Osteoporosis Association and the Endocrine Society of the Republic of China have jointly issued consensus statements on osteoporosis in diabetes, built from existing guidelines, current evidence and expert opinion.
The recommendations run along four lines. Screening should start earlier in people with diabetes than in the general population. Fracture risk calculation needs adjustment, because standard tools under-estimate risk in diabetes where bone microarchitecture and fall risk contribute independently of density. Anti-osteoporosis treatments work as well in diabetes as outside it - which is a useful and sometimes doubted point - and some agents may additionally improve glycaemic parameters. And the choice of antihyperglycaemic therapy should take skeletal effects into account, since agents differ in their impact on density and fracture. The document closes on system-level recommendations: multidisciplinary working, awareness, and integrating bone health into routine diabetes care.
This is consensus rather than evidence, assembled for a Taiwanese health system, and Indian practice differs in FRAX calibration, DXA access and the availability of anti-osteoporosis agents. What transfers is the framing, which is worth adopting whatever the local specifics: bone is a diabetes complication, and it belongs in the annual review alongside the eyes, the feet and the kidneys. In most clinics it is not there, and a fragility fracture in a person with diabetes is still routinely treated as an orthopaedic event rather than a metabolic one.
- Add bone health to the annual diabetes review, alongside retinal, foot and renal assessment
- Screen earlier for osteoporosis in diabetes than you would in the general population
- Use an adjusted fracture risk calculation rather than the uncorrected tool
- Factor skeletal effects into antihyperglycaemic drug selection, particularly in older patients with prior fracture
- Reassure patients that anti-osteoporosis treatment works as well in diabetes as it does without it
Why it matters
It names bone as a diabetes complication, which is the reframing that gets it assessed at all.
Don't overread it
Expert consensus assembled from existing guidelines for a Taiwanese health system - not new evidence, and not calibrated to Indian practice.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free